Do analysts prefer SBFM or PRFX?

Sunshine Biopharma currently has a consensus target price of $70.00, suggesting a potential upside of 7,892.69%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Sunshine Biopharma is more favorable than PainReform. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate RDHL or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RDHL or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A PainReform N/A N/A N/A

Do analysts recommend XRTX or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XRTX or PRFX more profitable?

PainReform's return on equity of 0.00% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -137.85% -108.16% PainReform N/A N/A N/A

Do analysts prefer PRFX or JAGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PRFX or JAGX more profitable?

PainReform has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Jaguar Animal Health -187.88% N/A -131.45%

Do analysts prefer ORGS or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ORGS or PRFX more profitable?

PainReform has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% PainReform N/A N/A N/A

PainReform (PRFX) Competitors

$1.00 +0.07 (+7.47%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.98 -0.02 (-2.40%)

As of 08:42 AM Eastern

Compare

PRFX vs. SBFM, RDHL, XRTX, JAGX, and ORGS

Should you buy PainReform stock or one of its competitors? PainReform's main competitors and comparable companies include Sunshine Biopharma (SBFM), Redhill Biopharma (RDHL), XORTX Therapeutics (XRTX), Jaguar Animal Health (JAGX), and Orgenesis (ORGS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PainReform compare to Sunshine Biopharma?

Sunshine Biopharma (NASDAQ:SBFM) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

PainReform has lower revenue, but higher earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.10	-$5.97M	-$10.15	N/A
PainReform	$31K	28.03	-$5.02M	-$736.66	N/A

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Sunshine Biopharma's average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company	Overall Sentiment
Sunshine Biopharma	Neutral
PainReform	Neutral

Sunshine Biopharma currently has a consensus target price of $70.00, suggesting a potential upside of 7,892.69%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Sunshine Biopharma is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. PainReform's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
PainReform	N/A	N/A	N/A

Sunshine Biopharma has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, PainReform has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Summary

Sunshine Biopharma and PainReform tied by winning 7 of the 14 factors compared between the two stocks.

How does PainReform compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Redhill Biopharma has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	11.39	-$430K	$900.00	0.00
PainReform	$31K	28.03	-$5.02M	-$736.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Redhill Biopharma's average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
PainReform	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
PainReform	N/A	N/A	N/A

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Redhill Biopharma has a beta of 4.96, suggesting that its share price is 396% more volatile than the broader market. Comparatively, PainReform has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Summary

Redhill Biopharma beats PainReform on 5 of the 8 factors compared between the two stocks.

How does PainReform compare to XORTX Therapeutics?

XORTX Therapeutics (NASDAQ:XRTX) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, XORTX Therapeutics had 4 more articles in the media than PainReform. MarketBeat recorded 4 mentions for XORTX Therapeutics and 0 mentions for PainReform. XORTX Therapeutics' average media sentiment score of 0.15 beat PainReform's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
XORTX Therapeutics	Neutral
PainReform	Neutral

XORTX Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

PainReform's return on equity of 0.00% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-137.85%	-108.16%
PainReform	N/A	N/A	N/A

XORTX Therapeutics has higher earnings, but lower revenue than PainReform. XORTX Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A
PainReform	$31K	28.03	-$5.02M	-$736.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PainReform beats XORTX Therapeutics on 7 of the 11 factors compared between the two stocks.

How does PainReform compare to Jaguar Animal Health?

PainReform (NASDAQ:PRFX) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

PainReform has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Jaguar Animal Health	-187.88%	N/A	-131.45%

37.3% of PainReform shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 0.2% of Jaguar Animal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has higher earnings, but lower revenue than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$31K	28.03	-$5.02M	-$736.66	N/A
Jaguar Animal Health	$11.51M	0.26	-$53.43M	-$248.88	N/A

In the previous week, Jaguar Animal Health had 17 more articles in the media than PainReform. MarketBeat recorded 17 mentions for Jaguar Animal Health and 0 mentions for PainReform. PainReform's average media sentiment score of 0.00 beat Jaguar Animal Health's score of -0.11 indicating that PainReform is being referred to more favorably in the media.

Company	Overall Sentiment
PainReform	Neutral
Jaguar Animal Health	Neutral

PainReform has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Jaguar Animal Health has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

Summary

PainReform beats Jaguar Animal Health on 9 of the 12 factors compared between the two stocks.

How does PainReform compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

PainReform has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
PainReform	N/A	N/A	N/A

Orgenesis has a beta of 3.16, meaning that its stock price is 216% more volatile than the broader market. Comparatively, PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
PainReform	Neutral

PainReform has lower revenue, but higher earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	4.53	-$55.36M	-$11.51	N/A
PainReform	$31K	28.03	-$5.02M	-$736.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 1.9% of Orgenesis shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

PainReform beats Orgenesis on 8 of the 11 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRFX vs. The Competition

Export

Metric	PainReform	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$808K	$12.61B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	0.00	792.28	274.10	25.70
Price / Sales	28.03	857.09	672.61	90.85
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.04	10.57	10.48	6.32
Net Income	-$5.02M	$2.81B	$3.49B	$359.73M
7 Day Performance	-1.96%	-0.17%	-0.68%	0.17%
1 Month Performance	-0.99%	-1.39%	-3.18%	-3.27%
1 Year Performance	-86.58%	2.83%	15.13%	5.58%

PainReform Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRFX PainReform	0.7225 of 5 stars	$1.00 +7.5%	N/A	-86.8%	$808K	$31K	N/A	7	Gap Up
SBFM Sunshine Biopharma	2.0994 of 5 stars	$0.88 -3.4%	$70.00 +7,892.7%	-94.5%	$3.40M	$36.31M	N/A	50	Positive News
RDHL Redhill Biopharma	1.1431 of 5 stars	$0.54 +0.4%	N/A	-66.5%	$3.30M	$290K	0.00	210	Gap Down
XRTX XORTX Therapeutics	0.8125 of 5 stars	$1.70 -8.6%	N/A	-60.9%	$3.09M	N/A	N/A	N/A	Analyst Forecast Gap Down
JAGX Jaguar Animal Health	0.4018 of 5 stars	$8.91 -74.1%	N/A	-99.2%	$3.03M	$11.51M	N/A	47	News Coverage Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRFX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PainReform (PRFX) Competitors

PRFX vs. SBFM, RDHL, XRTX, JAGX, and ORGS

How does PainReform compare to Sunshine Biopharma?

Summary

How does PainReform compare to Redhill Biopharma?

Summary

How does PainReform compare to XORTX Therapeutics?

Summary

How does PainReform compare to Jaguar Animal Health?

Summary

How does PainReform compare to Orgenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PainReform (PRFX) Competitors

PRFX vs. SBFM, RDHL, XRTX, JAGX, and ORGS

How does PainReform compare to Sunshine Biopharma?

Which has preferable earnings and valuation, SBFM or PRFX?

Do insiders and institutionals have more ownership in SBFM or PRFX?

Does the media favor SBFM or PRFX?

Do analysts prefer SBFM or PRFX?

Is SBFM or PRFX more profitable?

Which has more volatility and risk, SBFM or PRFX?

Summary

How does PainReform compare to Redhill Biopharma?

Which has stronger valuation and earnings, RDHL or PRFX?

Do analysts rate RDHL or PRFX?

Does the media refer more to RDHL or PRFX?

Is RDHL or PRFX more profitable?

Do institutionals & insiders have more ownership in RDHL or PRFX?

Which has more risk & volatility, RDHL or PRFX?

Summary

How does PainReform compare to XORTX Therapeutics?

Do institutionals and insiders have more ownership in XRTX or PRFX?

Does the media favor XRTX or PRFX?

Which has more risk & volatility, XRTX or PRFX?

Is XRTX or PRFX more profitable?

Which has stronger earnings and valuation, XRTX or PRFX?

Do analysts recommend XRTX or PRFX?

Summary

How does PainReform compare to Jaguar Animal Health?

Is PRFX or JAGX more profitable?

Do insiders & institutionals hold more shares of PRFX or JAGX?

Do analysts prefer PRFX or JAGX?

Which has stronger valuation & earnings, PRFX or JAGX?

Does the media prefer PRFX or JAGX?

Which has more risk and volatility, PRFX or JAGX?

Summary

How does PainReform compare to Orgenesis?

Is ORGS or PRFX more profitable?

Which has more risk & volatility, ORGS or PRFX?

Does the media refer more to ORGS or PRFX?

Which has stronger valuation & earnings, ORGS or PRFX?

Do analysts prefer ORGS or PRFX?

Do insiders and institutionals have more ownership in ORGS or PRFX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools